Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PP
Propanc Biopharma, Inc. Common Stock
PPCB
Mkt Cap
$3.3M
Volume
2.01M
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PP
PPCB
PP
Propanc Biopharma, Inc. Common Stock
PPCB
News
·
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
Mkt Cap
$3.4M
Volume
2.01M
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
Propanc Biopharma is pursuing a strategic initiative to acquire Digital Asset Treasury (DAT) companies trading below their market cap to net asset value, aiming to diversify its asset base and create shareholder value.
GlobeNewswire Inc. · Nov 4, 2025
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Propanc Biopharma secured a strategic financing agreement with Hexstone Capital for up to $100 million, involving convertible preferred stock and warrants to support clinical pipeline development and digital asset treasury strategy.
GlobeNewswire Inc. · Oct 15, 2025
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Propanc Biopharma successfully closed a public offering of 1,000,000 shares at $4.00 per share, raising $4 Million and commencing trading on the Nasdaq Capital Market under the ticker PPCB.
Benzinga · Aug 19, 2025
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
Propanc Biopharma announced a public offering of 1 million shares at $4.00 per share, expecting to raise approximately $4 million. The company will use proceeds for working capital and has received approval to list on Nasdaq Capital Market.
GlobeNewswire Inc. · Aug 15, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PP
PPCB
Propanc Biopharma, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PPCB
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PPCB yet.
Related Tickers
Earnings